1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Ulcerative Colitis [2017]

Ulcerative Colitis [2017]

  • September 2017
  • ID: 5214603
  • Format: PDF
  • By Firstword Pharma


Table of Contents

Will oral therapies transform the treatment of ulcerative colitis?

With Pfizer’s Xeljanz (tofacitinib) pending approval in the US, new oral therapies are set to transform the ulcerative colitis (UC) treatment landscape. While Pfizer’s JAK inhibitor clearly has a head-start, other companies have more selective JAK1-inhibitors in late-stage development, including AbbVie’s upadacitinib and Galapagos/Gilead Sciences’ filgotinib.

Celgene has taken a different approach with its oral molecule, ozanimod. Do KOLs believe they’ll all be successful? Other late-stage programmes, including Roche’s subcutaneous integrin inhibitor, etrolizumab, and Johnson & Johnson’s Stelara (ustekinumab), will also add complexity and choice to the treatment algorithm. How will these products fare in an increasingly competitive environment, where anti-TNF biosimilars look set to dominate? KOLs provide candid insights on these and other new therapies, their likely use, and how they’ll affect current mainstays such as anti-TNFs and Takeda’s Entyvio (vedolizumab), in KOL Insight: Ulcerative Colitis.

Twelve North American and European KOLs provide their insight on 5 marketed/registered products and 9 late-stage pipeline programmes.

Take a tour of the report now

The table of contents >
The key business questions answered >
The key KOL quotes >
See the therapies covered >
Find out who the 6 EU & 6 US KOLs are >
Review an extract from the report - 1 drug profile >

Top takeaways
• An addition to mild-to-moderate disease? Mild-to-moderate UC is currently treated with cheap, generic 5-ASA, but can Lipid Therapeutics’ LT-02 add clinical value? What do KOLs view as LT-02’s specific advantages?
• Optimism for biosimilar anti-TNFs continues to grow. An increasing number of KOLs are using these products. But in which patients are these agents used, and are they having an equal impact in both the US and EU markets?
• Etrolizumab set to challenge Entyvio? Roche’s etrolizumab is a subcutaneous integrin inhibitor undergoing late-stage evaluation. Do KOLs believe this agent will be a threat to Takeda’s Entyvio (vedolizumab)?
• Stelara (ustekinumab) will add more choice to the treatment algorithm. KOLs agree that Johnson & Johnson’s Stelara has shown great efficacy in Crohn’s disease. But can this translate to UC, and what are Stelara’s specific advantages?
• KOLs excited by the arrival of oral therapies. With Pfizer’s Xeljanz (tofacitinib) pending approval for UC in the US, several other JAK inhibitors in late-stage development and Celgene’s ozanimod in Phase III trials, KOLs are understandably excited. How are these agents expected to be used?
• Will enema formulations for moderate-to-severe disease succeed? InDex Pharmaceuticals’ Kappaproct (cobitolimod) and Atlantic Healthcare/Ionis Pharmaceuticals’ alicaforsen are being evaluated as potential enemas for moderate-to-severe disease. According to KOLs, how clinically and commercially attractive are these products?


“We were apprehensive [about biosimilar TNF inhibitors] at first. We had no experience using these products and the patients also had some doubts; patients saw the drug was cheaper, and for this reason, thought it was worse. Things have changed, and nowadays we have gained experience and we know that there is no difference between Remicade and biosimilar infliximab.” European Key Opinion Leader

Sample of therapies covered

Marketed/Registered Therapies
• Uceris/Cortiment (budesonide MMX; Cosmo/Salix/Ferring)
• Remicade (infliximab; Merck & Co./Johnson & Johnson)
• Humira (adalimumab; AbbVie)
• Simponi (golimumab; Merck & Co./Johnson & Johnson)
• Entyvio (vedolizumab; Takeda)

Pipeline (P3) Therapies
• LT-02 (phosphatidylcholine controlled-release; Lipid Therapeutics/Dr Falk Pharma/Nestlé Health Science)
• etrolizumab (RG 7413; Roche)
• Stelara (ustekinumab; Johnson & Johnson)
• Xeljanz (tofacitinib; Pfizer)
• upadacitinib (ABT 494; AbbVie)
• filgotinib (GLPG 0634; Galapagos/Gilead Sciences)
• ozanimod (RPC 1063; Celgene)
• Kappaproct (cobitolimod; InDex Pharmaceuticals)
• alicaforsen (Atlantic Healthcare/Ionis Pharmaceuticals)

KOLs interviewed

KOLs from North America
• Dr. Edward V. Loftus, Jr., MD, is a Professor of Medicine in the division of Gastroenterology at Mayo Clinic College of Medicine, Rochester, MN
• Dr. Hans Herfarth, MD, PhD, is a Professor of Medicine at University of North Carolina, Chapel Hill, NC
• Dr. Ashwin Ananthakrishnan, MBBS, MPH, is an Assistant Professor of Medicine at Harvard Medical School and is medical co-director at the MGH Crohn’s and Colitis center
• Dr. James Vecchio, MD, is a gastroenterologist in Burlington, Vermont and is affiliated with University of Vermont Health Network University of Vermont Medical Center
• Dr. Joseph D Feuerstein, MD, is an Assistant Professor of Medicine at Harvard Medical School. He is affiliated with Harvard Medical Faculty Physicians (HMFP) at Beth Israel Deaconess Medical Center
• Anonymous, US KOL, is a Professor of Medicine at a leading US university

KOLs from Europe
• Dr. Ayesha Akbar, MBChB, MRCP, PhD, is a Consultant Gastroenterologist at St. Mark’s Hospital and Academic Institute, London, UK
• Dr. Sami Hoque, FRCP, FRCPE, PhD, FACG, is a Consultant Gastroenterologist and Honorary Senior Lecturer at Queen Mary’s University of London, and Lead Physician for digestive disease and nutrition in Barts Health NHS trust, Whipps Cross University Hospital, London, UK
• Dr. T. Paupard, MD, is a Consultant at Centre Hospitalier Dunkerque, Dunkerque, France, and Head of Department of Hepato-Gastroenterology
• Dr. Silvio Danese, MD, PhD, is Head of the Inflammatory Bowel Disease Clinical and Research Unit at the Humanitas Research Hospital, Milan, Italy. He is also a Professor in Gastroenterology at Humanitas University, Milan, Italy
• Dr. Sonia Romero Izquierdo, MD, is a gastroenterologist who works in a university hospital in Spain
• Anonymous, German KOL, is a Professor at a leading German university hospital

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on